JAMA Cardiology
LightNews LightNews
banner
jamacardiology.com
JAMA Cardiology
@jamacardiology.com
200 followers 20 following 140 posts
JAMA Cardiology is a member of the JAMA Network, a consortium of peer-reviewed, general medical and specialty publications.

🌐 JAMACardiology.com
Posts Replies Media Videos
jamacardiology.com
Acoramidis demonstrated equivalent benefit for mortality and cardiovascular hospitalization in wild-type and variant ATTR-CM, including p.Val142Ile, over 42 months of follow-up.

ja.ma/3JTSjLO
Kaplan-Meier curves display the efficacy of acoramidis in treating wild-type and variant transthyretin amyloid cardiomyopathy. The graphs compare acoramidis to placebo. Each graph shows time since randomization vs survival probability.
November 11, 2025 at 11:00 AM
jamacardiology.com
From @jamanetworkopen.com: Among adults with symptoms after #COVID19 infection, a pragmatic, home-based resistance exercise program is a generalizable, safe, and effective therapy for improving physical and psychological function.

#AHA25 @ahascience.bsky.social

ja.ma/3XmnYZm
Infographic titled "RCT: Resistance Exercise Therapy After COVID-19 Infection." It highlights a study with 87 men and 146 women, median age 53.6, across 3 Scottish hospitals. Intervention results show improved outcomes vs. standard care.
November 10, 2025 at 8:29 PM
jamacardiology.com
From @jamanetworkopen.com: For home health aides (HHAs) caring for adults with #HeartFailure (HF), HF training improved HHA knowledge and self-efficacy, with greatest gains among those with the lowest baseline scores.

#AHA25 @ahascience.bsky.social

ja.ma/47zLpoa
Two graphs compare 'EUC' and 'Intervention' groups over time. Graph A shows DHFKS scores, both groups increase from baseline to postcourse. Graph B shows self-efficacy scores, with intervention scores initially higher and both groups remaining relatively stable.
November 10, 2025 at 8:09 PM
jamacardiology.com
Editor’s Note: Prospective pilot data by Jain et al validate an #AI model for ATTR-CM screening; real-world implementation challenges and outcome effects require further study.

#AHA25 @ahascience.bsky.social

ja.ma/4oxBPrT
JAMA Cardiology article: 'Implementation Intelligence With AI—Prospective Evaluations Needed' by Faraz S. Ahmad et al. Published online November 10, 2025. Discusses AI's role in detecting amyloid transthyretin cardiomyopathy (ATTR-CM).
November 10, 2025 at 8:05 PM
jamacardiology.com
#AI model ATTRACTnet improved detection of undiagnosed ATTR-CM, with a >2.8-fold higher diagnostic yield vs historical controls and increased system-wide case identification.

#AHA25 @ahascience.bsky.social

ja.ma/3WLzv4g
JAMA Cardiology article titled "Detecting Transthyretin Cardiac Amyloidosis With Artificial Intelligence." Includes two graphs: "Internal test set" showing multiple curves and "External test set" with one curve, plotting true vs. false positive rates.
November 10, 2025 at 8:00 PM
Reposted by JAMA Cardiology
jama.com
In this #AHA25 edition of the JAMA Editor’s Summary podcast, Gregory Curfman, MD, Philip Greenland, MD, and Robert Bonow, MD, MS, review key JAMA Network articles, including:

➡️ Coffee and #AFib,
➡️ DASH-patterned groceries,
➡️ Oral PCSK9 inhibitor enlicitide, and more.

🎧 Listen now: ja.ma/47MpAAj
Close-up of JAMA journals stacked. The covers feature 'JAMA' in bold letters. Below, text reads: 'From AHA: Coffee Consumption and Atrial Fibrillation, DASH-... JAMA Editors' Summary'. A purple 'Play' button is visible.
November 9, 2025 at 11:35 PM
Reposted by JAMA Cardiology
jama.com
💾 Save this thread! Check out these key findings from today's JAMA, @jamacardiology.com, @jamainternalmed.com, and
@jamanetworkopen.com presentations at #AHA25. 🧵

Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events. ja.ma/4oyzvko
Four graphs from a JAMA article titled 'Coronary Computed Tomography Angiography in Prediction of First Coronary Events'. The graphs show 'Cumulative Incidence of Coronary Events', charting coronary event rates by CACS, SIS, stenosis, and calcification.
November 9, 2025 at 11:20 PM
jamacardiology.com
Robert Bonow, MD, MS, is celebrated at #AHA25. Dr Bonow, founding editor of JAMA Cardiology, marked 10 years as its Editor in Chief.
Robert Bonow, MD, MS, is celebrated at #AHA25. Robert Bonow, MD, MS, is celebrated at #AHA25.
November 9, 2025 at 11:02 PM
jamacardiology.com
💬 Editorial from @jama.com: While early detection and treatment may help some high-risk youth, the study by Bellows et al suggests broader population approaches to lower LDL-C distribution may provide greater cost-effectiveness.

#AHA25 @ahascience.bsky.social

ja.ma/4owIqCV
An editorial from JAMA, published online November 9, 2025, titled "Childhood Cholesterol Screening Is Not Cost-Effective" by Matthew W. Gillman, MD, SM. The article discusses controversies and recommendations for hypercholesterolemia screening in youths.
November 9, 2025 at 10:40 PM
jamacardiology.com
From @jama.com: Sequential childhood or early adulthood screening for familial hypercholesterolemia may lower lifetime CVD risk, but is unlikely to be cost-effective unless follow-up for elevated cholesterol is widely implemented.

#AHA25 @ahascience.bsky.social

ja.ma/3WKUmEM
The JAMA article presents cost-effectiveness outcomes for familial hypercholesterolemia screening in children. Two graphs compare sequential screening to usual care, stratified by LDL-C threshold, with cost-effectiveness scatterplot and acceptability curve.
November 9, 2025 at 10:35 PM
jamacardiology.com
From @jamainternalmed.com: A 6-month habit-based group lifestyle intervention added to routine education and activity monitoring improved the proportion of patients with sustained metabolic syndrome remission.

#AHA25 @ahascience.bsky.social

ja.ma/3LONdRu
Line graph titled 'Metabolic Syndrome Remission, by Study Group and Time' shows remission percentages for 'Treatment' and 'Comparator' groups at 0, 6, and 24 months. The treatment group shows higher remission rates than the comparator group at all times.
November 9, 2025 at 10:31 PM
jamacardiology.com
💬 Editorial from @jama.com: The GoFresh trial showed home-delivered DASH groceries modestly lowered BP and LDL cholesterol in Black adults, but high costs and diet design limit broader impact.

#AHA25 @ahascience.bsky.social

ja.ma/4nKFu4m
An editorial from JAMA, published online November 9, 2025, titled "Medically Tailored Groceries for Blood Pressure Control: Promise, Progress, and Need for Optimal Design" by Dariush Mozaffarian, MD, DrPH. The article discusses food as medicine.
November 9, 2025 at 10:30 PM
jamacardiology.com
From @jama.com: Home-delivered, low-sodium Dietary Approaches to Stop Hypertension (DASH) groceries and dietitian support temporarily improved blood pressure and LDL cholesterol in Black adults with high BP versus monetary support.

#AHA25 @ahascience.bsky.social

ja.ma/4hXIMA4
Infographic summarizing a JAMA study on home-delivered groceries and blood pressure in Black adults. Key findings: DASH grocery delivery resulted in -5.7 mm Hg change, self-directed shopping -2.3 mm Hg. The between-group difference was -3.4 mm Hg.
November 9, 2025 at 10:25 PM
jamacardiology.com
💬 Editorial from @jama.com: The CORALreef HeFH trial demonstrated that oral enlicitide achieves reductions in LDL-C and other atherogenic lipids in patients w/ heterozygous familial hypercholesterolemia receiving statin therapy.

#AHA25 @ahascience.bsky.social

ja.ma/4owIhiR
JAMA article: 'Beyond Statins—Expanding the Arsenal of Lipid-Lowering Therapies' by Michelle L. O'Donoghue et al., published online November 9, 2025. Article discusses statins and new therapies for reducing cardiovascular risk.
November 9, 2025 at 10:20 PM
jamacardiology.com
From @jama.com: Among adults with HeFH who were already taking statin therapy, treatment with enlicitide was well tolerated and reduced levels of LDL-C, apolipoprotein B, non–HDL-C, and lipoprotein(a).

#AHA25 @ahascience.bsky.social

ja.ma/4nLNvG6
JAMA study: Oral PCSK9 inhibitor enlicitide reduces LDL cholesterol in adults with heterozygous familial hypercholesterolemia. 303 patients randomized, enlicitide group saw -58.2% change, placebo 2.6%.
November 9, 2025 at 10:15 PM
jamacardiology.com
From @jamanetworkopen.com: For neonates w/ congenital heart defects (CHDs) in Illinois, delayed #prenatal care initiation was associated with a higher probability of delivery at a pediatric #cardiac center, especially for severe CHD.

#AHA25 @ahascience.bsky.social

ja.ma/4nFWrNd
JAMA Network Open publication cover, November 9, 2025. Titled "Prenatal Care and Perinatal Regionalization for Congenital Heart Defects" by Christina Laternser et al. Highlights the association between prenatal care and delivery location for neonates.
November 9, 2025 at 6:50 PM
jamacardiology.com
From @jama.com: Adding coronary CT angiography to traditional risk scores modestly improved prediction of first coronary events in a large population-based study.

#AHA25 @ahascience.bsky.social

ja.ma/4nO5Nqv
JAMA article graphs showing cumulative coronary event rates over time. Graphs detail rates by CACS, SIS, stenosis, and calcification, comparing different levels and conditions. Higher CACS/SIS scores and stenosis percentages correlate with increased event rates.
November 9, 2025 at 6:40 PM
jamacardiology.com
💬 Invited Commentary: Flynn et al find non-DNMT3A clonal hematopoiesis of indeterminate potential (CHIP) mutations most strongly associated with heart failure risk in UK Biobank data, supporting gene-specific risk assessment.

#AHA25 @ahascience.bsky.social

ja.ma/4p56SeB
A JAMA Cardiology article, published November 9, 2025, titled "Clonal Hematopoiesis—An Opportunity to Confront the Heart Failure Epidemic" by Domingo A. Pascual-Figal and José J. Fuster, discusses the relationship between CHIP and heart failure.
November 9, 2025 at 6:10 PM
jamacardiology.com
Non-DNMT3A clonal hematopoiesis of indeterminate potential (CHIP) subtypes—including TET2, ASXL1, JAK2, and spliceosome genes—demonstrated higher association with incident heart failure compared to DNMT3A.

#AHA25 @ahascience.bsky.social

ja.ma/3JQSveI
JAMA Cardiology graph titled, "Clonal Hematopoiesis and Incident Heart Failure." It shows mediation analyses for clonal hematopoiesis of indeterminant potential(CHIP) and incident heart failure. Coronary artery disease, atrial fibrillation and combined model has highest %
November 9, 2025 at 6:05 PM
jamacardiology.com
Meta-analysis from @jamanetworkopen.com: Compared to standard regimens, trastuzumab emtansine exhibited a more favorable cardiotoxicity profile, while other novel and standard therapies demonstrated comparable risks of LVEF decline.

#AHA25 @ahascience.bsky.social

ja.ma/47N3Gx9
JAMA Network Open article, published November 9, 2025, titled 'Cardiotoxic Effects of Antibody Drug Conjugates vs Standard Chemotherapy in ERBB2-Positive Advanced Breast Cancer: A Systematic Review and Meta-Analysis'.
November 9, 2025 at 5:50 PM
jamacardiology.com
A randomized clinical trial published in JAMA found that patients with AF who consumed caffeinated coffee had a lower risk of recurrent AF or atrial flutter compared with those who abstained.

#AHA25 #AFib @ahascience.bsky.social

ja.ma/49GpXPu
November 9, 2025 at 5:00 PM
jamacardiology.com
📊 Research Summary from @jama.com: Adults with #AFib who drank at least one cup of caffeinated coffee daily after successful cardioversion had a lower risk of recurrence than those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/47Nwy8q
JAMA Research Summary: Caffeinated coffee consumption or abstinence to reduce atrial fibrillation. Coffee consumption had a 47% rate of recurrence of atrial flutter while coffee abstinence had a 64% rate over 6 months.
November 9, 2025 at 3:20 PM
jamacardiology.com
From @jama.com: Patients with #AFib who continued their usual caffeinated coffee intake after cardioversion experienced less recurrence of AF or atrial flutter compared to those who abstained from coffee and caffeine.

#AHA25 @ahascience.bsky.social

ja.ma/3JA3f15
Infographic from JAMA on caffeinated coffee's effect on atrial fibrillation. It concludes coffee consumption averaging 1 cup daily is associated with less AF recurrence versus abstinence. The study randomized 200 patients.
November 9, 2025 at 3:05 PM
Reposted by JAMA Cardiology
jama.com
🧵 #AHA25 attendees, check out these key findings from today's JAMA and @jamacardiology.com presentations:

Among people with PAD and no #diabetes, metformin treatment for 6 months did not result in improvements in walking ability or secondary outcomes vs placebo. ja.ma/4oqMJzr
November 9, 2025 at 2:25 AM
jamacardiology.com
💬 @jama.com Editorial: While restrictive transfusion remains standard, TOP trial results indicate some cardiac patients may benefit from a tailored approach based on clinical factors.

#AHA25 @ahascience.bsky.social

ja.ma/3JyJy9T
JAMA journal cover, "Postoperative Transfusion in Patients at High Cardiac Risk: Evidence, Uncertainty, and Nuance" by Jeremy W. Jacobs, MD, MHS; Evan M. Bloch, MBChB, MS. Published online November 8, 2025. An editorial section is highlighted.
November 8, 2025 at 10:25 PM